Zealand Pharma A/S (ZLDPF)
PNK · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Peers in Healthcare
Zealand Pharma A/S has no peer companies in this window.
Recent press releases
Zealand Pharma A/S has not issued a press release in this window.
SEC filings
All filings →Zealand Pharma A/S has not filed an SEC document in this window.
Insider trades
All insider trades →Zealand Pharma A/S has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Zealand Pharma A/S
All people →No officers or directors have been indexed for Zealand Pharma A/S.
Quarterly financials
Full financials →No quarterly financials have been ingested for Zealand Pharma A/S.